The new pathway elucidated here suggests that therapeutic administration of an LTB4/BLT1 pathway antagonist may be beneficial for improving HDL-mediated anti-inflammatory and pro-resolving functions in cardiovascular disease patients. The gene discussed is LTB4R; the disease is cardiovascular disorder.